假设所有配售股份获悉数配售，配售的估计所得款项总额及所得款项净额(经扣除本公司将承担的相关 成本及开支后)将分别为约3亿港元及约2.96亿港元。其中：1.约40%，构建新一代智能化研发与数据平 台;2.约28%，偿还贷款及强化本公司资本结构;3.约12%，持续及计划研发PB-2301及PB-2309;4.约10%， 设立香港附属公司及加快本集团海外业务布局;5.约10%，一般公司用途及营运资金。 假设于本公告日期至完成日期期间本公司的已发行股本并无变动，513.6万股配售股份之总数相当于： (i)本公告日期已发行H股的约1.84%及已发行股份总数的约1.33%;及(ii)经配发及发行配售股份扩大的H 股的约1.81%及股份总数的约1.31%。配售价为每股配售股份58.41港元，较H股于2025年12月12日(香港 时间)(即配售协议日期)在联交所所报的收市价每股64.90港元折让10%。 派格生物医药-B(02565)发布公告，于2025年12月12日(交易时段后)，本公司与联席配售代理订立配售协 议，据此，本公司已有条件同意透过联席配售代理按尽力基准以每股配售股份58.41港元的价格向不少 于六名承配人配售 ...

Group 1 - The company, Paig BioPharma-B (02565.HK), has entered into a placement agreement with joint placement agents, CITIC Securities and ABC International, to issue 5.136 million shares at a price of HKD 58.41 per share, representing a discount of 10% from the closing price of HKD 64.90 on December 12 [1][2] - The total number of shares to be placed represents approximately 1.84% of the company's issued H shares and about 1.33% of the total issued shares as of the announcement date [1] - If all placement shares are fully placed, the estimated gross proceeds will be approximately HKD 300 million, with net proceeds expected to be around HKD 296 million [2] Group 2 - Approximately 40% of the net proceeds is intended for the construction of a next-generation intelligent research and data platform [2] - About 28% of the net proceeds will be used to repay loans and strengthen the company's capital structure [2] - The remaining proceeds will be allocated for ongoing and planned research of PB-2301 and PB-2309 (12%), establishing a subsidiary in Hong Kong and accelerating overseas business expansion (10%), and general corporate purposes and working capital (10%) [2]

假设所有配售股份获悉数配售，配售的估计所得款项总额及所得款项净额(经扣除本公司将承担的相关 成本及开支后)将分别为约3亿港元及约2.96亿港元。其中：1.约40%，构建新一代智能化研发与数据平 台;2.约28%，偿还贷款及强化本公司资本结构;3.约12%，持续及计划研发PB-2301及 PB-2309;4.约10%， 设立香港附属公司及加快本集团海外业务布局;5.约10%，一般公司用途及营运资金。 智通财经APP讯，派格生物医药-B(02565)发布公告，于2025年12月12日(交易时段后)，本公司与联席配 售代理订立配售协议，据此，本公司已有条件同意透过联席配售代理按尽力基准以每股配售股份58.41 港元的价格向不少于六名承配人配售合共513.6万股配售股份，该等配售股份将由本公司根据一般授权 按配售协议所载条款及条件发行。 假设于本公告日期至完成日期期间本公司的已发行股本并无变动，513.6万股配售股份之总数相当于： (i)本公告日期已发行H股的约1.84%及已发行股份总数的约1.33%;及(ii)经配发及发行配售股份扩大的H 股的约1.81%及股份总数的约1.31%。配售价为每股配售股份58.41港元 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本，均不得直接或間接在美國境內發佈或分發，亦不得在任何其他司法管轄 區內發佈或分發，而此類發佈或分發於該等司法管轄區可能屬違法。 本公告並不構成在美國購買或認購證券的任何要約或要約招攬，亦不構成其一部分。本公告所 述證券並無亦不會根據1933年美國證券法（經修訂）（「美國證券法」）或美國任何其他適用證券 法律登記，且除非已根據美國證券法登記，或依照美國證券法或美國任何其他適用證券法律獲 豁免登記，或在無須根據美國證券法或美國任何其他適用證券法律登記的交易中，否則不得在 美國發售、出售或以其他方式轉讓。本公司無意在美國進行任何證券公開發售。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 根據一般授權配售新H股 整體協調人兼聯席配售代理 資 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 派格生物醫藥 ( 杭州 ) 股份有限公司 第 1 頁 共 11 頁 v 1.1.1 FF301 由於本公司是中華人民共和國註冊成立的股份有限公司，因此「法定股本」的概念並不適用。第一部分所載資料所指的是「註冊股本」。 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02565 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 279,164,339 | RMB | | | 1 RMB | | 279,164,339 | | 增加 / 減少 ( ...

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, which represents approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion of unlisted shares into H-shares is aimed at increasing liquidity and potentially enhancing shareholder value [1] - The application to the regulatory body indicates the company's strategic move towards expanding its capital market presence [1] - The conversion process reflects the company's ongoing efforts to align with market practices and improve its financial structure [1]

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, representing approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of 102 million unlisted shares [1] - The conversion will result in the issuance of H-shares, which are traded on the Hong Kong Stock Exchange [1] - The newly converted shares will account for about 26.35% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert approximately 101.7 million unlisted shares held by 20 shareholders into H-shares based on a one-to-one ratio, which represents about 26.35% of the total issued shares as of the announcement date [1] Group 1 - The conversion involves 20 shareholders and a total of approximately 101.7 million unlisted shares [1] - The conversion will result in these shares being transformed into H-shares, expanding the company's capital structure [1] - The application has been submitted to the China Securities Regulatory Commission for approval [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 本公告乃派格生物醫藥（杭州）股份有限公司（「本公司」）根據香港聯合交易所有限 公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章 證券及期貨條例第XIVA部作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2023年8月10日發佈的《H股公 司境內未上市股份申請「全流通」業務指引》（中國證監會公告[2023]50號）（「該指 引」），內容有關H股於聯交所上市的公司申請境內未上市股份（定義見該指引）在 聯交所流通的程序。 根據該指引，本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司已於2025年 11月28日就按一比一的基準將本公司20名股東持有的合共101,702,051股未上市股 份（「未上市股份」）轉換為本公司H股 ...

Core Viewpoint - The stock of Pagoda Biopharmaceuticals-B (02565.HK) opened over 7% higher on November 27, closing at HKD 70.00 per share, an increase of 7.03% due to the announcement of an extended lock-up period by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [2] Group 1: Lock-up Period Extension - Yizhe Kangrui has agreed not to reduce its holdings of H-shares from the original lock-up expiration date until December 31, 2025, extending the lock-up period by 35 days [3] - The extension reflects Yizhe Kangrui's confidence in Pagoda Biopharmaceuticals' technological advancements and significant progress in major clinical milestones [2][3] - Yizhe Kangrui currently holds 9.5845 million H-shares, representing approximately 3.43% of the total issued H-shares of the company [3] Group 2: Company Background and Recent Developments - Pagoda Biopharmaceuticals, established in 2008, focuses on the research and development of innovative therapies for chronic diseases, particularly in the field of metabolic disorders [5] - The company recently received approval for its first product, PB-119 (Vepidna Injection), aimed at improving blood sugar control in adults with type 2 diabetes [6] - Since its listing, Pagoda Biopharmaceuticals has seen a stock price increase of 438.46% over 129 trading days from May 27 to the present [6] Group 3: Financial Performance and Market Outlook - Pagoda Biopharmaceuticals has reported losses of CNY 279 million, CNY 283 million, and CNY 93.62 million for the years 2023, 2024, and the first half of 2025, respectively [6] - A recent report from Softbank China has given Pagoda Biopharmaceuticals a strong buy rating with a target price of HKD 101.80, citing the clinical advantages of PB-119 and potential revenue growth from 2026 to 2029 [6]